iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Dr. Reddys hits 52-week low; falls 5% in four days

24 Feb 2022 , 12:09 PM

Shares of Dr. Reddys have declined nearly 5.2% in four trading sessions from its previous closing high of Rs 4,321 posted on 18 February 2022. The counter has fallen nearly 27% from its 52-week high of Rs 5613.65 hit on 7 July 2021. The stock hit a 52-week low of Rs 4,055.85 in intraday today.

In one month, the stock has fallen 6.1% as compared to a 3.4% fall in Nifty 50 index.

The counter came under selling pressure amid rising geopolitical tensions in Russia and Ukraine. Russian President Vladimir Putin announced military action on Thursday. The company has a strong presence in Russia and Europe overall. Revenues from Europe market stood at Rs 410 crore in Q3 FY22. The drug maker also partnered with Russian Direct Investment Fund (RDIF) for the development of Sputnik V vaccine.

On the technical front, the stocks RSI (relative strength index) stood at 30.626. The RSI oscillates between zero and 100. Traditionally the RSI is considered overbought when above 70 and oversold when below 30.

The stock is trading above its 50 and 100 days simple moving average placed at 4517.64 and 4626.56 respectively. These levels will act as crucial support zones in near term.

Dr. Reddys Laboratories is an integrated pharmaceutical company. It offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddys operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe.

The drug maker reported a consolidated net profit of Rs 706.50 crore in Q3 FY22, steeply higher than 19.80 crore in Q3 FY21. On a consolidated basis, the companys revenue from operations rose 7.91% to Rs 5319.70 crore in in Q3 FY22 over Q3 FY21.

Powered by Capital Market – Live News

Related Tags

  • capital market
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.